Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Metals Report
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
Companies Commented On
- Aastrom Biosciences Inc.
- Alkermes plc
- Anthera Pharmaceuticals Inc.
- BioMarin Pharmaceuticals
- Celgene Corp.
- Coronado Biosciences
- Cyclacel Pharmaceuticals Inc.
- ImmunoGen Inc.
- Incyte Corp.
- Isis Pharmaceuticals Inc.
- Nektar Therapeutics
- Novavax Inc.
- OncoGenex Pharmaceuticals Inc.
- Pharmacyclics Inc.
- Sangamo BioSciences Inc.
- Teva Pharmaceutical Industries Ltd.
John McCamant is the editor of the Medical Technology Stock Letter, a leading investment newsletter in August 2000. McCamant has spent 25 years on the frontlines of biotechnology investing. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Reuters, Bloomberg, CBS and Marketwatch.
The Medical Technology Stock Letter has earned the #1 ranking from Hulbert's Financial Digest. >Read More
Six Superstars for Your Biotech Portfolio: John McCamant (5/9/13) We are in the "golden age," of biotech, and Medical Technology Stock Letter Editor John McCamant has innovative ideas on how to glean profits from the renaissance. Investors should be looking at companies with excellent management and platform technologies that offer multiple opportunities for success. McCamant names his favorites in this interview with The Life Sciences Report, including one company with a radical therapy that harkens back to the days before the reign of hand sanitizer.
The Life Sciences Report Watchlist 2013 (1/31/13) Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their experience in the space, could determine which companies have the best chances for upward stock price movement. The result is the groundbreaking Life Sciences Report Watchlist 2013. In this exclusive article, you can follow the thought process that went into generating the short list, and learn more about the potential winners and what they are poised to accomplish in the next 12 months.
Out of the Red and into the Black: John McCamant on Investment in Blood Cancer Companies (10/25/12) Hematological cancers present special opportunities for investors. In this exclusive interview with The Life Sciences Report, John McCamant, editor of the Medical Technology Stock Letter, comments on several companies in the hematology/oncology space, describing the challenges and successes that influence investment in the sector. In the case of two companies with very different valuations, McCamant makes his preference clear.
"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >